Trial intelligence / Profile preview

Pilot study of oral glatiramer acetate in relapsing-remitting multiple sclerosis

2004-000462-13Phase 2Completed

Sponsor
Teva Pharmaceutical Industries Ltd.
Start
Jul 2004
Modality
Recombinant Proteins and Enzymes, Peptides
Countries
1
01

Overview

Phase 2, open-label, single-arm trial of glatiramer acetate in multiple sclerosis (MS), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Total number of T1 gadolinium-enhancing lesions. Started Jul 2004; status: completed.

02

Drugs

glatiramer acetate
03

Conditions

multiple sclerosis (MS)

Beyond the preview

Go deeper on 2004-000462-13.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2004-000462-13.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call